FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2062865670> ?p ?o ?g. }

• W2062865670 endingPage "1489" @default.
• W2062865670 startingPage "1487" @default.
• W2062865670 abstract "We read with interest the review by Welker and Zeuzem1 on occult hepatitis C virus (HCV) infection and replies by Carreño et al.2 and Halfon et al.3 and would like to make our contribution to this topic regarding precisely the role of occult HCV infection in immune-compromised patients. Recently, Barrill et al. found that 45% of 109 anti-HCV–negative hemodialysis patients with abnormal serum aminotranferases had HCV RNA in peripheral blood mononuclear cells (PBMCs),4 but no data are so far available on occult HCV infection in oncohematological patients. We prospectively enrolled 28 consecutive anti-HCV–negative patients with an oncohematological disease who first underwent chemotherapy from April 2006 to November 2007. All patients were screened for hepatitis B surface antigen (HBsAg), anti-HBs (antibody to hepatitis B surface antigen), anti-HBc (antibody to hepatitis B core antigen), and anti-HCV. The diagnosis and treatment of the oncohematological diseases were based on commonly accepted criteria. For each patient, samples of plasma and PBMCs were obtained at enrollment, at months 1 and 3 during chemotherapy, and then every 3 months after treatment discontinuation. The 28 patients were treated with chemotherapy for 4-12 months and observed after its discontinuation for 6-24 months. PBMCs were isolated from 5 mL whole blood by means of Histopaque (Sigma-Aldrich, St. Louis, MO) according to a standard technique and collected in aliquots of 2 × 106 cells. The presence of HCV RNA in plasma and PBMCs of all samples collected during the study was determined as previously reported.5 The detection limit in the plasma samples was around 40 IU/mL. The sensitivity of our method to detect HCV RNA in PBMC samples was assessed using HCV-positive PBMCs diluted in PBMCs obtained from an HCV RNA–negative patient, as described by Halfon et al.6 Briefly, 2 × 106 PBMCs from an HCV RNA–positive patient quantified at 1.8 × 104 IU/2 × 106 PBMCs was sequentially diluted (1:10) in 2 × 106 HCV RNA–negative PBMCs; in these PBMC mixtures, HCV RNA was then quantified by real-time polymerase chain reaction. The lowest detection limit by this method was 18 IU/2 × 106 cells. As a positive control for extraction of RNA from PBMCs, glucose-6-phosphate dehydrogenase (G6PDH) messenger RNA was sought in all PBMC samples collected (LightCycler h-G6PDH Housekeeping Gene Set; Roche Diagnostics, Branchburg, NJ). Table 1 shows the demographic, clinical, biochemical, and serological characteristics observed at the baseline in the 28 patients enrolled (Table 1). The three HBsAg-/HBV DNA–positive patients at the baseline were treated with telbivudine or entecavir. They became HBV DNA–negative within 6 months while still under treatment and remained so throughout the observation; the 16 HBsAg-negative/anti-HBc–positive patients received lamivudine prophylaxis and never showed circulating HBsAg or HBV DNA. No plasma or PBMC sample collected during the study was HCV RNA–positive. All PBMC samples collected were positive for G6PDH messenger RNA. No patient in the present study became positive for HCV RNA in plasma or PBMCs while under chemotherapy for an oncohematological disease. The data from this longitudinal study run counter to the existence of occult HCV infection in patients under strong immunosuppression, who constitute a suitable model of investigation to explore occult HCV infection. In addition, 60.7% of the patients enrolled received rituximab-based chemotherapy, which has been demonstrated as able to increase the HCV replication in anti-HCV–positive patients.7 In conclusion, neither occult HCV infection nor its reactivation under strong immunosuppressive chemotherapy were found in the present study in oncohematological patients who were anti-HCV- and HCV RNA–negative. Our data and those of others6, 8 suggest the nonexistence of occult HCV infection. Nicola Coppola M.D., Ph.D.*, Mariantonietta Pisaturo M.D.*, Salvatore Guastafierro M.D. , Gilda Tonziello M.D.*, Antonello Sica M.D., Ph.D. , Caterina Sagnelli Ph.D.*, Maria Giovanna Ferrara M.D. , Evangelista Sagnelli M.D.* , * Department of Public Medicine, Section of Infectious Diseases, Naples, Italy, Haematology Unit, Second University of Naples, Naples, Italy, Division of Infectious Diseases, Azienda Ospedaliera Sant'Anna e San Sebastiano di Caserta, Caserta, Italy." @default.
• W2062865670 created "2016-06-24" @default.
• W2062865670 creator A5013783352 @default.
• W2062865670 creator A5046084823 @default.
• W2062865670 creator A5057200062 @default.
• W2062865670 creator A5059942169 @default.
• W2062865670 creator A5061888532 @default.
• W2062865670 creator A5064010931 @default.
• W2062865670 creator A5066445066 @default.
• W2062865670 creator A5073085176 @default.
• W2062865670 date "2011-08-24" @default.
• W2062865670 modified "2023-09-23" @default.
• W2062865670 title "Absence of occult hepatitis C virus infection in patients under immunosupressive therapy for oncohematological diseases" @default.
• W2062865670 cites W1576983632 @default.
• W2062865670 cites W1975976410 @default.
• W2062865670 cites W2001481948 @default.
• W2062865670 cites W2016414950 @default.
• W2062865670 cites W2110493572 @default.
• W2062865670 cites W2132247387 @default.
• W2062865670 cites W2149075545 @default.
• W2062865670 cites W2411490292 @default.
• W2062865670 doi "https://doi.org/10.1002/hep.24436" @default.
• W2062865670 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21608002" @default.
• W2062865670 hasPublicationYear "2011" @default.
• W2062865670 type Work @default.
• W2062865670 sameAs 2062865670 @default.
• W2062865670 citedByCount "34" @default.
• W2062865670 countsByYear W20628656702012 @default.
• W2062865670 countsByYear W20628656702013 @default.
• W2062865670 countsByYear W20628656702014 @default.
• W2062865670 countsByYear W20628656702015 @default.
• W2062865670 countsByYear W20628656702019 @default.
• W2062865670 countsByYear W20628656702020 @default.
• W2062865670 countsByYear W20628656702021 @default.
• W2062865670 countsByYear W20628656702022 @default.
• W2062865670 crossrefType "journal-article" @default.
• W2062865670 hasAuthorship W2062865670A5013783352 @default.
• W2062865670 hasAuthorship W2062865670A5046084823 @default.
• W2062865670 hasAuthorship W2062865670A5057200062 @default.
• W2062865670 hasAuthorship W2062865670A5059942169 @default.
• W2062865670 hasAuthorship W2062865670A5061888532 @default.
• W2062865670 hasAuthorship W2062865670A5064010931 @default.
• W2062865670 hasAuthorship W2062865670A5066445066 @default.
• W2062865670 hasAuthorship W2062865670A5073085176 @default.
• W2062865670 hasBestOaLocation W20628656701 @default.
• W2062865670 hasConcept C126322002 @default.
• W2062865670 hasConcept C137061746 @default.
• W2062865670 hasConcept C142724271 @default.
• W2062865670 hasConcept C159654299 @default.
• W2062865670 hasConcept C202751555 @default.
• W2062865670 hasConcept C203014093 @default.
• W2062865670 hasConcept C204787440 @default.
• W2062865670 hasConcept C2522874641 @default.
• W2062865670 hasConcept C2776408679 @default.
• W2062865670 hasConcept C2776455275 @default.
• W2062865670 hasConcept C2776694085 @default.
• W2062865670 hasConcept C2777410769 @default.
• W2062865670 hasConcept C2778715236 @default.
• W2062865670 hasConcept C2780593183 @default.
• W2062865670 hasConcept C520017518 @default.
• W2062865670 hasConcept C55493867 @default.
• W2062865670 hasConcept C71924100 @default.
• W2062865670 hasConcept C86803240 @default.
• W2062865670 hasConcept C90924648 @default.
• W2062865670 hasConceptScore W2062865670C126322002 @default.
• W2062865670 hasConceptScore W2062865670C137061746 @default.
• W2062865670 hasConceptScore W2062865670C142724271 @default.
• W2062865670 hasConceptScore W2062865670C159654299 @default.
• W2062865670 hasConceptScore W2062865670C202751555 @default.
• W2062865670 hasConceptScore W2062865670C203014093 @default.
• W2062865670 hasConceptScore W2062865670C204787440 @default.
• W2062865670 hasConceptScore W2062865670C2522874641 @default.
• W2062865670 hasConceptScore W2062865670C2776408679 @default.
• W2062865670 hasConceptScore W2062865670C2776455275 @default.
• W2062865670 hasConceptScore W2062865670C2776694085 @default.
• W2062865670 hasConceptScore W2062865670C2777410769 @default.
• W2062865670 hasConceptScore W2062865670C2778715236 @default.
• W2062865670 hasConceptScore W2062865670C2780593183 @default.
• W2062865670 hasConceptScore W2062865670C520017518 @default.
• W2062865670 hasConceptScore W2062865670C55493867 @default.
• W2062865670 hasConceptScore W2062865670C71924100 @default.
• W2062865670 hasConceptScore W2062865670C86803240 @default.
• W2062865670 hasConceptScore W2062865670C90924648 @default.
• W2062865670 hasIssue "4" @default.
• W2062865670 hasLocation W20628656701 @default.
• W2062865670 hasLocation W20628656702 @default.
• W2062865670 hasOpenAccess W2062865670 @default.
• W2062865670 hasPrimaryLocation W20628656701 @default.
• W2062865670 hasRelatedWork W2004742623 @default.
• W2062865670 hasRelatedWork W2050919004 @default.
• W2062865670 hasRelatedWork W2081775579 @default.
• W2062865670 hasRelatedWork W2089849620 @default.
• W2062865670 hasRelatedWork W2135783877 @default.
• W2062865670 hasRelatedWork W2417504320 @default.
• W2062865670 hasRelatedWork W3005179357 @default.
• W2062865670 hasRelatedWork W3033489338 @default.
• W2062865670 hasRelatedWork W3108049206 @default.
• W2062865670 hasRelatedWork W4307830291 @default.

• next